Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Recent advances for the treatment of cocaine abuse: Central nervous system immunopharmacotherapy

  • Published:
The AAPS Journal Aims and scope Submit manuscript

This article was retracted on 15 May 2012

Abstract

Cocaine addiction continues to be a major health and societal problem in spite of governmental efforts devoted toward educating the public of the dangers of illicit drug use. A variety of pharmacotherapies and psychosocial programs have been proposed in an effort to provide a method for alleviation of the physical and psychological symptoms of cocaine abuse. Unfortunately, these methods have been met with limited success, illustrating a critical need for new effective approaches for the treatment of cocaine addiction. Recently an alternative cocaine abuse treatment strategy was proposed using intranasal administration of an engineered filamentous bacteriophage displaying cocaine-sequestering antibodies on its surface. These phage particles are an effective vector for CNS penetration and are capable of binding cocaine, thereby blocking its behavioral effects in a rodent model. The convergence of phage display and immunopharmacotherapy has allowed for an investigation of the efficacy of protein-based therapeutics acting within the CNS on the effects of cocaine in animal models and has uncovered a new tool in the battle against cocaine addiction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Koob GF. Neurobiology of addiction. Toward the development of new therapies.Ann NY Acad Sci. 2000;909:170–185.

    Article  PubMed  CAS  Google Scholar 

  2. Weiss F., Koob GF. Drug addiction: functional neurotoxicity of the brain reward systems.Neurotoxic Res. 2001;3:145–156.

    Article  CAS  Google Scholar 

  3. Melichar JK, Daglish MRC, Nutt DJ. Addiction and withdrawalcurrent views.Curr Opin Pharmacol. 2001;1:84–90.

    Article  PubMed  CAS  Google Scholar 

  4. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status.Trends Neurosci. 1999;22:521–527.

    Article  PubMed  CAS  Google Scholar 

  5. Di Chiana G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation.Drug Alcohol Depend. 1995;38:95–137.

    Article  Google Scholar 

  6. Johanson C-E, Fischman MW. The pharmacology of cocaine related to its abuse.Pharmacol Rev. 1989;41:3–52.

    PubMed  CAS  Google Scholar 

  7. Blaine JD, Ling W. Psychopharm acologic treatment of cocaine dependence.Psychopharmacol Bull. 1992;28:11–14.

    PubMed  CAS  Google Scholar 

  8. Substance Abuse and Mental Health Services Administration, Office of Applied Studies,Preliminary estimates from the 1992 Household Survey on Drug Abuse.Advance Report No. 3. Washington, DC: US Department of Health and Human Services, Public Health Service, June 1993.

    Google Scholar 

  9. Cregler LL, Herbert M. Medical complications of cocaine abuse.N Engl J Med. 1986;315:1495–1500.

    Article  PubMed  CAS  Google Scholar 

  10. Des Jarlais DC, Friedman SR. AIDS and i.v. drug use.Science. 1989;245:578–579.

    Article  PubMed  Google Scholar 

  11. Lee JH, Bennett G. Substaance abuse in adulthood. In: Bennett G, Woolf D, ed.Substance Abuse: Pharmacologic, Developmental and Clinical Perspectives. Albany: Delman Publishing, 1991:157–170.

    Google Scholar 

  12. Walsh SL. Behavioral pharmacology of cocaine. In: Tarter RE, Ammerman RT, Ott PJ, eds.Handbook of Substance Abuse: Neurobehavioral Pharmacology: New York: Plenum; 1998:187–200.

    Chapter  Google Scholar 

  13. Mendelson JH, Mello NK. Management of cocaine abuse and dependence.N Engl J Med. 1996;334:965–972.

    Article  PubMed  CAS  Google Scholar 

  14. Gorelick DA. Pharmacologic interventions for cocaine, crack, and other stimulant addiction. In: Graham AW, Schultz TK, eds.,Principles of Addiction Medicine. Chevy Chase, MD. American Society of Addiction Medicine; 2003:89–111.

    Google Scholar 

  15. Gorelick DA, Gardner EL, Xi Z-X. Agents in the development for the management of cocaine abuse.Drugs. 2004;64:1547–1573.

    Article  PubMed  CAS  Google Scholar 

  16. Leiderman DB, Shoptaw S, Montgomery A, et al. Cocaine rapid efficacy screening trial (CREST). A paradigm for the controlled evaluation of candidate medications for cocaine dependence.Addiction. 2005;100:1–11.

    Article  PubMed  Google Scholar 

  17. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertaline and donepezil as cocaine dependence treatment.Addiction. 2005;100:68–77.

    Article  PubMed  Google Scholar 

  18. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.Addiction. 2003;98:1625–1632

    Article  PubMed  Google Scholar 

  19. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.Arch Gen Psychiatry 2004;61:264–272.

    Article  PubMed  CAS  Google Scholar 

  20. Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions.Psychopharmacology (Berl). 2004;172:31–40.

    Article  PubMed  CAS  Google Scholar 

  21. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use.J Clin Psychiatry. 2003;64:1440–1448.

    Article  PubMed  CAS  Google Scholar 

  22. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence.Drug Alcohol Depend. 2004;75:233–240.

    Article  PubMed  CAS  Google Scholar 

  23. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity.Drug Alcohol Depend. 2001;63:69–78.

    Article  PubMed  CAS  Google Scholar 

  24. Hoffman JA III, Caudill BD III, Koman JJ III, Luckey JW, Flynn PM, Hubbard RL. Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure.J Addict Dis. 1994;13:115–128.

    Article  PubMed  CAS  Google Scholar 

  25. Cashman JR. Biocatalysts in detoxication of drug of abuse.NIDA Res Monogr. 1997;173:225–258.

    PubMed  CAS  Google Scholar 

  26. Carrera MRA, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active immunization.Nature. 1995;378:727–730.

    Article  PubMed  CAS  Google Scholar 

  27. Carrera MRA, Ashley JA, zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model.Proc Natl Acad Sci USA. 2000;97:6202–6206.

    Article  PubMed  CAS  Google Scholar 

  28. Carrera MRA, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine.Proc Natl Acad Sci USA. 2001;98:1988–1992.

    Article  PubMed  CAS  Google Scholar 

  29. Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models.Nat Med. 1996;2:11129–11132.

    Google Scholar 

  30. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model.Psychopharmacology (Berl.) 2000;148:251–262.

    Article  CAS  Google Scholar 

  31. Landry DW, Zhao K, Yang GX-P, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine.Science. 1993;259:1899–1901.

    Article  PubMed  CAS  Google Scholar 

  32. Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (−)-cocaine obtained by a high-throughput procedure.J Pharmacol Exp Ther. 2000;293:952–961.

    PubMed  CAS  Google Scholar 

  33. Yang G, Chun J, Arakawa-Uramoto H, et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity.J Am Chem. Soc. 1996;118:5880–5890.

    Google Scholar 

  34. Baird TJ, Deng S-X, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats.J Pharmacol Exp Ther. 2000;295:1127–1134.

    PubMed  CAS  Google Scholar 

  35. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: the primary importance of linker effects.Bioorg Med Chem Lett. 2001;11:87–90.

    Article  PubMed  CAS  Google Scholar 

  36. Isomura S., Hoffman TZ, Wirsching P, Janda KD. Synthesis, properties, and reactivity of cocaine benzoylthioester possessing the cocaine absolute configuration.J Am Chem Soc. 2002;124:3661–3668.

    Article  PubMed  CAS  Google Scholar 

  37. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse.Curr Drug Discov Tech. 2004;1:77–89.

    Article  CAS  Google Scholar 

  38. Haney M, Kosten TR. Therapeutic vaccines for substance dependence.Expert Rev Vaccines. 2004;3:11–18.

    Article  PubMed  CAS  Google Scholar 

  39. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy.Drug Alcohol Depend. 1997;48:159–165.

    Article  PubMed  CAS  Google Scholar 

  40. Mattes CE, Belendiuk GW, Lynch TJ, Brady RO, Dretchen KL. Butyrylcholinesterase: an enzyme antidote for cocaine intoxication.Addict Biol. 1998;3:171–188.

    Article  CAS  Google Scholar 

  41. Nachon F, Nicolet Y, Viquie N, Masson P, Fontecilla-Camps JD, Lockridge O. Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization.Eur J Biochem. 2002;269:630–637.

    Article  PubMed  CAS  Google Scholar 

  42. Mattes CE, Lynch TJ, Singh A, et al. Therapeutic use of butyrylcholinesterase for cocaine intoxication.Toxicol Appl Pharmacol. 1997;145:372–380.

    Article  PubMed  CAS  Google Scholar 

  43. Sun H, Pang Y-P, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase.Mol Pharmacol. 2002;62:220–224.

    Article  PubMed  CAS  Google Scholar 

  44. Larocca D, Burg MA, Jensen-Pergakes K, Ravey PE, Gonzales AM, Baird A. Evolving phage vectors for cell targeted gene delivery.Curr Pharm Biotechnol. 2002;3:45–57.

    Article  PubMed  CAS  Google Scholar 

  45. Smith GP. Filamentous fusion phage, novel expression vectors that display cloned antigens on the virion surface.Science. 1985;228:1315–1317.

    Article  PubMed  CAS  Google Scholar 

  46. Carlton RM. Phage therapy: past history and future prospects.Arch Immunol Ther Exp (Warsz). 1999;47:267–274.

    PubMed  CAS  Google Scholar 

  47. Smith HW, Huggins RB. Successful treatment of experimental E coli infections in mice using phage: it general superiority over antibiotics.J Gen Microbiol. 1982;128:307–318.

    PubMed  CAS  Google Scholar 

  48. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowski A. Results in bacteriophage treatment of suppurative bacterial infections in the years 1981–1986.Arch Immunol Ther Exp (Warsz). 1986;35:569–583.

    Google Scholar 

  49. Stone R. Stalin’s forgotten cure.Science. 2002;298:728–731.

    Article  PubMed  CAS  Google Scholar 

  50. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries.Nature. 1996;380:364–366.

    Article  PubMed  CAS  Google Scholar 

  51. Essler M, Ruoslahti E.. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculatures.Proc Natl Acad Sci USA. 2002;99:2252–2257.

    Article  PubMed  CAS  Google Scholar 

  52. Dabrowska K., Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A. Bacteriophage penetration in vertebrates.J Appl Microbiol. 2005;98:7–13.

    Article  PubMed  CAS  Google Scholar 

  53. Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain.Proc Natl Acad Sci USA. 2002;99:5675–5679.

    Article  PubMed  CAS  Google Scholar 

  54. Gao C, Mao S, Lo C-HL, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays.Proc Natl Acad Sci USA. 1999;96:6025–6030.

    Article  PubMed  CAS  Google Scholar 

  55. Gao C, Mao S, Kaufmann G, Wirsching P, Lerner RA, Janda KD. A method for the generation of combinatorial antibody libraries using pIX phage display.Proc Natl Acad Sci USA. 2002;99:12612–12616.

    Article  PubMed  CAS  Google Scholar 

  56. Carrera MRA, Kaufmann GF, Mee JM, Meijler MM, Koob GF, Janda KD. Treating cocaine addiction with viruses.Proc Natl Acad Sci USA. 2004;101:10416–10421.

    Article  PubMed  CAS  Google Scholar 

  57. Barbas CF, Burton DR, Scott JK, Silverman GJ.Phage Display: A Laboratory Manual: Tuebingen, Germany: Cold Spring Harbor Laboratory Press; 2001.

    Google Scholar 

  58. Lyon M, Robbins TW. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Essman W, Valzelli L, eds.,Current Developments in Psychopharmacology. vol. 4. New York: Spectrum; 1975:79–163.

    Google Scholar 

  59. Illum L, Davis SS. Polymeric lamellar substrate particles for intranasal vaccination.Adv Drug Deliv Res. 2001;51:97–111.

    Article  Google Scholar 

  60. Jones N. The nose and paranasal sinuses physiology and anatomy.Adv Drug Deliv Rev. 2001;51:5–19.

    Article  PubMed  CAS  Google Scholar 

  61. Bresler MM, Rosser SJ, Basran A, Bruce NC. Gene cloning and nucleotide sequencing and properties of a cocaine esterase fromRhodococcus sp strain MB1.Appl Environ Microbiol. 2000;66:904–908.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Skaggs Institute for Chemical Biology and Department of Chemistry, The Scripps Research Institute, 10550 North Torry Pines Road, 92037, La Jolla, CA

    Tobin J. Dickerson & Kim D. Janda

  2. Department of Immunology, The Scripps Research Institute, 10550 North Torry Pines Road, 92037, La Jolla, CA

    Tobin J. Dickerson & Kim D. Janda

Authors
  1. Tobin J. Dickerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim D. Janda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim D. Janda.

Additional information

Published: October 19, 2005

A retraction note to this article is available at http://dx.doi.org/10.1208/s12248-012-9365-2.

This article has been retracted because of a substantial degree of duplication with "Bacteriophage-mediated protein delivery into the central nervous system and its application in immunopharmacotherapy. Expert Opin Biol Ther. 2005 Jun;5(6) 773–781."

An erratum to this article is available at http://dx.doi.org/10.1208/s12248-012-9365-2.

About this article

Cite this article

Dickerson, T.J., Janda, K.D. RETRACTED ARTICLE: Recent advances for the treatment of cocaine abuse: Central nervous system immunopharmacotherapy. AAPS J 7, 59 (2005). https://doi.org/10.1208/aapsj070359

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/aapsj070359

Keywords

Search

Navigation